May 22, 2022

Medical Trend

Medical News and Medical Resources

How long can patients with breast cancers live in different stages?

How long can patients with breast cancers live in different stages?



 

How long can patients with breast cancers live in different stages?

 

According to statistics, more than 80% of breast cancer patients can survive for at least 10 years, and the main difference between different survival periods is clinical stage and molecular type.

 

Clinical staging is relatively simple and easy to understand, that is, cancer cells in the early stage are relatively limited, patients live longer, and the spread of late stage increases, and the survival time is short.

 

How long can patients with breast cancers live in different stages?

 

According to statistics from the National Cancer Institute, patients diagnosed with breast cancer between 2007 and 2013, The survival time of each clinical stage is as follows:

  • The 5-year survival rate for women with stage 0 or 1 breast cancer is close to 100%.
  • For women with stage 2 breast cancer, the 5-year relative survival rate is approximately 93%.
  • The 5-year relative survival rate for stage 3 breast cancer is approximately 72%.
  • The 5-year relative survival rate for metastatic or stage 4 breast cancer is approximately 22%.

 

 

In addition to clinical staging, molecular typing is also an important factor, so what is molecular typing?

The molecular typing of breast cancer in clinical applications is mainly based on the expression status of ER, PR and HER2 proteins on the surface of cancer cells detected by immunohistochemistry, which are divided into 4 types:

  • Luminal A subtype (ER+/PR+, HER2–)
  • Luminal B subtype (ER+/PR+, HER2+)
  • HER2 positive (ER–/PR–/HER2+)
  • Triple negative type (ER–/PR–/HER2–)

 

The importance of molecular typing is closely related to the biological characteristics of the typing and the available treatment options.

For example, ER/PR hormone receptor-positive breast cancer is the most common type (appelled Luminal A and B subtypes), accounting for about 60%-70% of breast cancers, and it is also the slowest-growing subtype, Its treatment is mainly surgery + chemotherapy + endocrine therapy, and anti-estrogen therapy alone can play an anti-cancer effect.

It can be said that this classification is a “top student” that increases the average survival time.

 

But for triple-negative breast cancer patients, the survival time is significantly shorter. David G. Cox of France conducted a large cohort study (StoRM), they followed 1250 patients to study the relationship between genes and breast cancer metastasis, and the results confirmed that the mortality risk of early breast cancer patients increased with As the tumor type changes, the time from disease progression to tumor metastasis and death is shorter in triple-negative breast cancer (TNBC);

these patients have an average survival time of less than 24 months after tumor metastasis, while luminal and HER2-positive Even if the patient metastasized, the survival time was still more than 36 months.

 

In addition to these reasons, the survival rate of breast cancer patients is also related to a variety of other factors, including the degree of differentiation of the cancer cells, general health, and treatment.

 

With the development of medical technology, new drugs, new therapies, screening with higher sensitivity and specificity, the continuous research and development, promotion and popularization of inspection technologies, it is believed that the survival time of breast cancer patients will be longer and longer in the future.

 

 

 

How long can patients with breast cancers live in different stages?

(source:internet, reference only)


Disclaimer of medicaltrend.org